GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Cyclically Adjusted PS Ratio

MiMedx Group (MiMedx Group) Cyclically Adjusted PS Ratio : 2.92 (As of May. 15, 2024)


View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group Cyclically Adjusted PS Ratio?

As of today (2024-05-15), MiMedx Group's current share price is $7.9999. MiMedx Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $2.74. MiMedx Group's Cyclically Adjusted PS Ratio for today is 2.92.

The historical rank and industry rank for MiMedx Group's Cyclically Adjusted PS Ratio or its related term are showing as below:

MDXG' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.88   Med: 3.35   Max: 17.26
Current: 2.87

During the past years, MiMedx Group's highest Cyclically Adjusted PS Ratio was 17.26. The lowest was 0.88. And the median was 3.35.

MDXG's Cyclically Adjusted PS Ratio is ranked better than
64.91% of 513 companies
in the Biotechnology industry
Industry Median: 5.58 vs MDXG: 2.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MiMedx Group's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.565. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.74 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


MiMedx Group Cyclically Adjusted PS Ratio Historical Data

The historical data trend for MiMedx Group's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Cyclically Adjusted PS Ratio Chart

MiMedx Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.96 5.11 2.86 1.14 3.24

MiMedx Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 2.53 2.72 3.24 2.81

Competitive Comparison of MiMedx Group's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, MiMedx Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiMedx Group's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Cyclically Adjusted PS Ratio falls into.



MiMedx Group Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

MiMedx Group's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=7.9999/2.74
=2.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiMedx Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, MiMedx Group's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.565/129.4194*129.4194
=0.565

Current CPI (Mar. 2024) = 129.4194.

MiMedx Group Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.242 100.560 0.311
201409 0.297 100.428 0.383
201412 0.342 99.070 0.447
201503 0.359 99.621 0.466
201506 0.400 100.684 0.514
201509 0.428 100.392 0.552
201512 0.462 99.792 0.599
201603 0.476 100.470 0.613
201606 0.511 101.688 0.650
201609 0.573 101.861 0.728
201612 0.409 101.863 0.520
201703 0.638 102.862 0.803
201706 0.652 103.349 0.816
201709 0.720 104.136 0.895
201712 0.763 104.011 0.949
201803 0.740 105.290 0.910
201806 0.859 106.317 1.046
201809 0.821 106.507 0.998
201812 0.848 105.998 1.035
201903 0.625 107.251 0.754
201906 0.631 108.070 0.756
201909 0.811 108.329 0.969
201912 0.714 108.420 0.852
202003 0.574 108.902 0.682
202006 0.496 108.767 0.590
202009 0.593 109.815 0.699
202012 0.633 109.897 0.745
202103 0.548 111.754 0.635
202106 0.618 114.631 0.698
202109 0.570 115.734 0.637
202112 0.458 117.630 0.504
202203 0.528 121.301 0.563
202206 0.593 125.017 0.614
202209 0.597 125.227 0.617
202212 0.654 125.222 0.676
202303 0.627 127.348 0.637
202306 0.701 128.729 0.705
202309 0.685 129.860 0.683
202312 0.594 129.419 0.594
202403 0.565 129.419 0.565

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MiMedx Group  (NAS:MDXG) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


MiMedx Group Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of MiMedx Group's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MiMedx Group (MiMedx Group) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Executives
Rice Doug officer: Chief Financial Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper officer: Chief Executive Officer BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein officer: EVP, Research and Development C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson officer: Chief Financial Officer BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan officer: Chief Accounting Officer 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv officer: General Counsel 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow officer: Chief Operating Officer C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap officer: EVP & Chief Commercial Officer 8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright director, officer: Chief Executive Officer C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves officer: SVP & Chief Compliance Officer 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner officer: SVP, Operations & Procurement 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani director 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604